These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27362390)

  • 1. Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
    Farkowski MM; Maciąg A; Żurawska M; Pytkowski M; Kowalik I; Woźniak J; Sterliński M; Szwed H
    Pol Arch Med Wewn; 2016 Jun; 126(6):381-7. PubMed ID: 27362390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
    Farkowski MM; Maciag A; Zurawska M; Kowalik I; Szwed H; Pytkowski M
    Cardiovasc Ther; 2018 Dec; 36(6):e12469. PubMed ID: 30281920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.
    Wybraniec MT; Wróbel W; Wilkosz K; Wrona K; Bula K; Mizia-Stec K
    J Am Heart Assoc; 2018 Oct; 7(20):e010153. PubMed ID: 30371270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
    Wybraniec MT; Maciąg A; Miśkowiec D; Ceynowa-Sielawko B; Balsam P; Wójcik M; Wróbel W; Farkowski M; Ćwiek-Rębowska E; Szołkiewicz M; Ozierański K; Błaszczyk R; Bula K; Dembowski T; Peller M; Krzowski B; Wańha W; Koziński M; Kasprzak JD; Szwed H; Mizia-Stec K
    Pol Arch Intern Med; 2022 Jun; 132(6):. PubMed ID: 35293200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
    Ceynowa-Sielawko B; Wybraniec MT; Topp-Zielińska A; Maciąg A; Miśkowiec D; Balsam P; Wójcik M; Wróbel W; Farkowski MM; Ćwiek-Rębowska E; Ozierański K; Błaszczyk R; Bula K; Dembowski T; Peller M; Krzowski B; Wańha W; Koziński M; Kasprzak JD; Szwed H; Mizia-Stec K; Szołkiewicz M
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients.
    Farkowski MM; Maciąg A; Żurawska M; Kołakowski K; Gardziejczyk P; Kowalik I; Szwed H; Pytkowski M
    Pol Arch Intern Med; 2022 Jan; 132(1):. PubMed ID: 34643078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
    Zhang HC; Guo JH; Fang Q; Zheng YA; Sun YM; Zhu WQ; Wan Z; Guo JX; Ge JB; Han SM
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):798-801. PubMed ID: 15949393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
    Farkowski MM; Maciag A; Dabrowski R; Pytkowski M; Kowalik I; Szwed H
    Trials; 2012 Sep; 13():162. PubMed ID: 22967497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation.
    Zapolski T; Wysokiński A
    Kardiol Pol; 2005 Sep; 63(3):254-62; discussion 263-4. PubMed ID: 16180181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced interatrial block is associated with recurrence of atrial fibrillation post pharmacological cardioversion.
    Enriquez A; Conde D; Hopman W; Mondragon I; Chiale PA; de Luna AB; Baranchuk A
    Cardiovasc Ther; 2014 Apr; 32(2):52-6. PubMed ID: 24417765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
    Bonora A; Turcato G; Franchi E; Taioli G; Dilda A; Zerman G; Maccagnani A; Pistorelli C; Olivieri O
    Intern Emerg Med; 2017 Sep; 12(6):853-859. PubMed ID: 27384766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation.
    Balsam P; Koźluk E; Peller M; Piątkowska A; Lodziński P; Kiliszek M; Kołtowski Ł; Grabowski M; Opolski G
    Adv Med Sci; 2015 Sep; 60(2):231-5. PubMed ID: 25919055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
    Maciag A; Farkowski MM; Chwyczko T; Beckowski M; Syska P; Kowalik I; Pytkowski M; Wozniak J; Dabrowski R; Szwed H
    Europace; 2017 Oct; 19(10):1637-1642. PubMed ID: 28339554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).
    Farkowski MM; Maciag A; Kowalik I; Konka M; Szwed H; Pytkowski M
    Br J Clin Pharmacol; 2019 Jul; 85(7):1552-1558. PubMed ID: 30920001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium].
    Márk L; Erdej F; Dani G; Borbély M; Sziklai G; Nagy E; Hajdara I; Katona A
    Orv Hetil; 2004 May; 145(19):1001-6. PubMed ID: 15181735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.
    Korantzopoulos P; Kolettis TM; Papathanasiou A; Naka KK; Kolios P; Leontaridis I; Draganigos A; Katsouras CS; Goudevenos JA
    Heart; 2006 May; 92(5):631-4. PubMed ID: 16159973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
    Fragakis N; Papadopoulos N; Papanastasiou S; Kozirakis M; Maligkos G; Tsaritsaniotis E; Katsaris G
    Pacing Clin Electrophysiol; 2005 Sep; 28(9):954-61. PubMed ID: 16176535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland.
    Kiliszek M; Opolski G; Włodarczyk P; Dąbrowski R; Ponikowski P
    Cardiol J; 2014; 21(5):484-91. PubMed ID: 24526513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
    Aliot E; Denjoy I
    Am J Cardiol; 1996 Jan; 77(3):66A-71A. PubMed ID: 8607394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation.
    Kochiadakis GE; Igoumenidis NE; Hamilos ME; Marketou ME; Chlouverakis GI; Vardas PE
    Am J Cardiol; 2007 Jun; 99(12):1721-5. PubMed ID: 17560882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.